Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT04028479
Official study title

The Registry of Oncology Outcomes Associated With Testing and Treatment

Study summary

This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBiomarker Testing (L) and Systemic Treatment (T)

Plus 1 other study approaches.

Who it may be forMesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 18, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Taproot Health

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Taproot Health
Interventions being studied
Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Mesothelioma→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patient or representative provides written informed consent
  • Patient is diagnosed with advanced malignancy
  • Patient is willing to be treated for this malignancy according to a plan determine by them and their physician
  • patient will be willing to have regular follow up visits as part of their standard of care
Reasons someone may not be able to joinExclusion criteria

patient is not a candidate or does not desire any treatment for their disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Teton Cancer InstituteIdaho Falls, Idaho
  • Oncology and Hematology of South TexasLaredo, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 18, 2024. Always confirm current availability with the study team.

View original record ↗